How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)? ➡️75 pts with ARDs 💉2-week #MTX discontinuation after each dose of RZV ⏩Significant boost in immune response without difference in flare rates Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be

• https://x.com/DrMiniDey/status/1858609875758010555/photo/1

Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4

• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1
• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1

A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK

• https://x.com/ericdeinmd/status/1858577759452180634/photo/1
• https://x.com/ericdeinmd/status/1858577759452180634/photo/1

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

• https://x.com/RHEUMarampa/status/1858580860238217419/photo/1

A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe

• https://x.com/ericdeinmd/status/1858584654712017059/photo/1
• https://x.com/ericdeinmd/status/1858584654712017059/photo/1

A#2647 DADA2 cohort 101 pts in India Median delay dx 5 years - 5 pts of >20 yr - 39 pts w GI involvement- bad outcomes Skin most common - largely livedo, then ulcers/nodules CNS common w ischemia Many Rx before dx 12 deaths (11.8%) - 8 GI, 3 CVA, 1 suicide #ACR24 @RheumNow https://t.co/Q8kiVbJq8I

• https://x.com/ericdeinmd/status/1858603919494050241/photo/1
• https://x.com/ericdeinmd/status/1858603919494050241/photo/1

Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs

• Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients…
• https://x.com/RichardPAConway/status/1858606100754407799/photo/1

SmPCs recommend interrupting immunosuppression (IS) in infection What happens if you continue the drug? Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection Could continuation be a safe option in some pts? #ACR24 @RheumNow https://t.co/14SN6a4Wm8

• https://x.com/DrMiniDey/status/1858606604293468406/photo/1

RIP to Glucocorticoids in GPA For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0

• RIP to Glucocorticoids in GPA | RheumNow